+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future



Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future



Current Treatment Options in Oncology 15(1): 41-54



The natural history of HER2-positive breast cancer significantly changed in the past 15 years. Form being the most aggressive type of breast cancer, it became treatable with important cure rates. However, with new and successful drugs, resistance emerges. Progress in research and drug development continues to make available effective anti-HER2 therapies. Our challenge today is to use these tools correctly by looking at the data that support the indications of each compound and to continue clinical trial participation.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051396470

Download citation: RISBibTeXText

PMID: 24323591

DOI: 10.1007/s11864-013-0262-4


Related references

Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions. Reviews on Recent Clinical Trials 2(2): 111-116, 2007

Targeting the Human Epidermal Growth Factor Receptor 2 (Her2) in the Treatment of Breast Cancer: Recent Advances and Future Directions. Reviews on Recent Clinical Trials 2(2): 111-116, 2007

Targeting HER2: recent developments and future directions for breast cancer patients. Seminars in Oncology 28(6 Suppl 18): 21-29, 2001

Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treatment Reviews 39(3): 219-229, 2013

Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions. Future Oncology 8(2): 135-144, 2012

Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer. Asia-Pacific Journal of Clinical Oncology 14(Suppl. 4): 12-21, 2018

Advances in targeting HER2-positive breast cancer. Current Opinion in Obstetrics and Gynecology 30(1): 55-59, 2018

Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. Discovery Medicine 21(113): 65-74, 2016

Future options in the treatment of ErbB2 HER2-positive breast cancer. EJC Suppl.s 6(5): 25-31, 2008

Management of metastatic HER2-positive breast cancer: present and future. Bulletin du Cancer 97(3): 365-383, 2010

HER2-positive breast cancer: current and future treatment strategies. Drugs 67(9): 1329-1341, 2007

Recent advances in the management of lung and breast cancer. Future directions. Seminars in Oncology 17(4 Suppl 7): 50-52, 1990

A Tumor initiating cell-enriched prognostic signature for HER2+:ERα- breast cancer; rationale, new features, controversies and future directions. Oncotarget 4(8): 1317-1328, 2013

Neoadjuvant therapy for HER2-positive early-stage breast cancer: the future is almost here. Oncology 26(1): 26 28-9, 2012

Targeting HER2 in ovarian and uterine cancers: challenges and future directions. Gynecologic Oncology 135(2): 364-370, 2014